These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7890771)

  • 1. Limited and defined truncation at the C terminus enhances receptor binding and degranulation activity of the neutrophil-activating peptide 2 (NAP-2). Comparison of native and recombinant NAP-2 variants.
    Ehlert JE; Petersen F; Kubbutat MH; Gerdes J; Flad HD; Brandt E
    J Biol Chem; 1995 Mar; 270(11):6338-44. PubMed ID: 7890771
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel C-terminally truncated isoforms of the CXC chemokine beta-thromboglobulin and their impact on neutrophil functions.
    Ehlert JE; Gerdes J; Flad HD; Brandt E
    J Immunol; 1998 Nov; 161(9):4975-82. PubMed ID: 9794434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel molecular variant of the neutrophil-activating peptide NAP-2 with enhanced biological activity is truncated at the C-terminus: identification by antibodies with defined epitope specificity.
    Brandt E; Petersen F; Flad HD
    Mol Immunol; 1993 Aug; 30(11):979-91. PubMed ID: 7688853
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Down-regulation of neutrophil functions by the ELR(+) CXC chemokine platelet basic protein.
    Ehlert JE; Ludwig A; Grimm TA; Lindner B; Flad HD; Brandt E
    Blood; 2000 Nov; 96(9):2965-72. PubMed ID: 11049972
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin-activated human platelets release two NAP-2 variants that stimulate polymorphonuclear leukocytes.
    Piccardoni P; Evangelista V; Piccoli A; de Gaetano G; Walz A; Cerletti C
    Thromb Haemost; 1996 Nov; 76(5):780-5. PubMed ID: 8950790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural requirements of platelet chemokines for neutrophil activation.
    Yan Z; Zhang J; Holt JC; Stewart GJ; Niewiarowski S; Poncz M
    Blood; 1994 Oct; 84(7):2329-39. PubMed ID: 7919350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Purification, crystallization and preliminary X-ray diffraction analysis of recombinant human neutrophil-activating peptide 2 (rhNAP-2).
    Kungl AJ; Machius M; Huber R; Schwer C; Lam C; Aschauer H; Ehn G; Lindley IJ; Auer M
    FEBS Lett; 1994 Jun; 347(2-3):300-3. PubMed ID: 8034022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between neutrophil-binding affinity and suitability for infection imaging: comparison of (99m)Tc-labeled NAP-2 (CXCL-7) and 3 C-terminally truncated isoforms.
    Rennen HJ; Frielink C; Brandt E; Zaat SA; Boerman OC; Oyen WJ; Corstens FH
    J Nucl Med; 2004 Jul; 45(7):1217-23. PubMed ID: 15235069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure and bioactivity of recombinant human CTAP-III and NAP-2.
    Proudfoot AE; Peitsch MC; Power CA; Allet B; Mermod JJ; Bacon K; Wells TN
    J Protein Chem; 1997 Jan; 16(1):37-49. PubMed ID: 9055206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular cloning and characterisation of a neutrophil chemotactic protein from porcine platelets.
    Power CA; Proudfoot AE; Magnenat E; Bacon KB; Wells TN
    Eur J Biochem; 1994 Apr; 221(2):713-9. PubMed ID: 7513641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neutrophil-activating proteins interleukin 8 and beta-thromboglobulin: in vitro and in vivo comparison of NH2-terminally processed forms.
    Van Damme J; Rampart M; Conings R; Decock B; Van Osselaer N; Willems J; Billiau A
    Eur J Immunol; 1990 Sep; 20(9):2113-8. PubMed ID: 2145175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemokine regulation of human megakaryocytopoiesis.
    Gewirtz AM; Zhang J; Ratajczak J; Ratajczak M; Park KS; Li C; Yan Z; Poncz M
    Blood; 1995 Oct; 86(7):2559-67. PubMed ID: 7670101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Connective tissue-activating peptide III desensitizes chemokine receptors on neutrophils. Requirement for proteolytic formation of the neutrophil-activating peptide 2.
    Härter L; Petersen F; Flad HD; Brandt E
    J Immunol; 1994 Dec; 153(12):5698-708. PubMed ID: 7989767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-activating peptides NAP-2 and IL-8 bind to the same sites on neutrophils but interact in different ways. Discrepancies in binding affinities, receptor densities, and biologic effects.
    Petersen F; Flad HD; Brandt E
    J Immunol; 1994 Mar; 152(5):2467-78. PubMed ID: 8133058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The CXC chemokines growth-regulated oncogene (GRO) alpha, GRObeta, GROgamma, neutrophil-activating peptide-2, and epithelial cell-derived neutrophil-activating peptide-78 are potent agonists for the type B, but not the type A, human interleukin-8 receptor.
    Ahuja SK; Murphy PM
    J Biol Chem; 1996 Aug; 271(34):20545-50. PubMed ID: 8702798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Production of chemokines CTAPIII and NAP/2 by digestion of recombinant ubiquitin-CTAPIII with yeast ubiquitin C-terminal hydrolase and human immunodeficiency virus protease.
    Mildner AM; Paddock DJ; LeCureux LW; Leone JW; Anderson DC; Tomasselli AG; Heinrikson RL
    Protein Expr Purif; 1999 Jul; 16(2):347-54. PubMed ID: 10419831
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generation of the neutrophil-activating peptide-2 by cathepsin G and cathepsin G-treated human platelets.
    Cohen AB; Stevens MD; Miller EJ; Atkinson MA; Mullenbach G
    Am J Physiol; 1992 Aug; 263(2 Pt 1):L249-56. PubMed ID: 1387511
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biological and kinetic characterization of recombinant human macrophage inflammatory peptides 2 alpha and beta and comparison with the neutrophil activating peptide 2 and interleukin 8.
    Kurdowska A; Cohen AB; Carr FK; Stevens MD; Miller EJ; Mullenbach G; Tekamp-Olson P
    Cytokine; 1994 Mar; 6(2):124-34. PubMed ID: 8031995
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXC chemokines connective tissue activating peptide-III and neutrophil activating peptide-2 are heparin/heparan sulfate-degrading enzymes.
    Hoogewerf AJ; Leone JW; Reardon IM; Howe WJ; Asa D; Heinrikson RL; Ledbetter SR
    J Biol Chem; 1995 Feb; 270(7):3268-77. PubMed ID: 7852412
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Generation of the neutrophil-activating peptide NAP-2 from platelet basic protein or connective tissue-activating peptide III through monocyte proteases.
    Walz A; Baggiolini M
    J Exp Med; 1990 Feb; 171(2):449-54. PubMed ID: 2406364
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.